Logo

Axxam Opts for Spotfire DecisionSite

Jun 30, 2003

NEW YORK, June 30 - Milan-based biotech firm Axxam has licensed Spotfire's DecisionSite software, Spotfire said today.

 

Axxam is using an application based on Spotfire's DecisionSite for Lead Discovery software to analyze data produced by Molecular Devices' FLIPR (Fluorometric Imaging Plate Reader) system, Spotfire said.

 

Axxam is also using DecisionSite for Functional Genomics to discover and validate new genomic targets.

Breaking News
The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.